PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN


Paz-Ares L., Goldman J. W. , Garassino M. C. , Dvorkin M., Trukhin D., Statsenko G., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 September - 01 October 2019, cilt.30, ss.928-929

  • Cilt numarası: 30
  • Basıldığı Şehir: Barcelona
  • Basıldığı Ülke: İspanya
  • Sayfa Sayısı: ss.928-929